<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HE5A6DC86DF444DD88838FBB47EFC80B1" public-private="public" key="H" bill-type="olc">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 6973 IH: Enhanced Access to Affordable Medicines Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-03-08</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
<congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session>
<legis-num display="yes">H. R. 6973</legis-num>
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
<action display="yes">
<action-date date="20220308">March 8, 2022</action-date>
<action-desc><sponsor name-id="C001103">Mr. Carter of Georgia</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action>
<legis-type>A BILL</legis-type>
<official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to clarify the conditions under which the Secretary of Health and Human Services can approve generic drug applications with labeling temporarily different than the brand name drug, and for other purposes.</official-title>
</form>
<legis-body id="H5C3A700BE2364BA18C20D004CBE2BBA8" style="OLC"> 
<section id="H1B07AB956C1B474B9219B9A99470A67B" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Enhanced Access to Affordable Medicines Act of 2022</short-title></quote>.</text></section> <section id="H466046337AB94C42A588F48E427CB7D9"><enum>2.</enum><header>Clarifying the conditions of generic drug application approval for last-minute brand name drug labeling changes</header> <text display-inline="no-display-inline">Section 505(j)(10)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(10)(A)</external-xref>) is amended by striking clauses (i) through (iv) and inserting the following:</text> 
<quoted-block style="OLC" id="H7A045EEB92924B0B8A22456435FC9B30" display-inline="no-display-inline"> 
<clause id="H3806F0F38BB0445891916CE752F73DEA" indent="up2"><enum>(i)</enum><text display-inline="yes-display-inline">the application is otherwise eligible for approval under this subsection except thatâ€” </text> <subclause id="HDC966A0AC2D3498CA7D4450C596DDD74"><enum>(I)</enum> <item id="H2E601B22A9C442A0AF04155E356DBF0A" display-inline="yes-display-inline"><enum>(aa)</enum><text display-inline="yes-display-inline">the listed drug has an active patent, the listed drug has an active exclusivity period, or there is a delay in approval as described in paragraph (5)(B)(iii); and</text></item> 
<item id="H0508894F0964445BA94E459B282A4833" indent="up1"><enum>(bb)</enum><text>a revision to the labeling of the listed drug has been approved by the Secretary within 90 days of expiration of a patent, exclusivity period, or delay in approval referenced in item (aa); or</text></item></subclause> <subclause id="HC0EFCA4447024974AF6AF327BEFAEF5F"><enum>(II)</enum><text>a revision to the labeling of the listed drug has been approved by the Secretary, within 90 days of when the application is otherwise eligible for approval under this subsection;</text></subclause></clause> 
<clause id="HBF036D53AA1748F98ED6EBEE5F332686" indent="up2"><enum>(ii)</enum><text display-inline="yes-display-inline">the sponsor of the application agrees to submit revised labeling for the drug that is the subject of the application not later than 60 days after approval under this subsection of the application; and</text></clause> <clause id="H3DC3AB413DB74A3B974923225656F845" indent="up2"><enum>(iii)</enum><text display-inline="yes-display-inline">the labeling revision described under clause (i) does not include a change to the <quote>Warnings</quote> section of the labeling.</text> </clause><after-quoted-block>.</after-quoted-block></quoted-block></section> 
</legis-body>
</bill> 

